Sharyn D Baker, PharmD, PhD
Leadership Title: Associate Director, Shared Resources Gertrude Parker Heer Chair in Cancer Research
Academic Title: Professor & Chair
Research Program: Leukemia and Hematologic Malignancies
About Me
More info forI am a member of the Leukemia Research Leukemia and Hematologic Malignancies Program at the OSUCCC – James, where my research broadly covers translational and clinical pharmacology of anticancer agents. I also hold the Gertrude Parker Heer Chair in Cancer Research.
Recently, my laboratory has focused on the preclinical development of anticancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations.
I am also interested in studying developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anticancer drug disposition and investigational anticancer drug development.
I have authored or co-authored publications in several scientific journals, including Cancer Research, Leukemia, Clinical Pharmacology & Therapeutics, Journal of Clinical Investigation and Nature Communications.
Academic Office & Contact Information
More info forAcademic Office:
Riffe Building R0512
496 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-6016Email:
baker.2480@osu.eduPublications
More info forAugust 29, 2024Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen.
Drabison T, Boeckman M, Yang Y, Huang KM, de Bruijn P, Nepal MR, Silvaroli JA, Chowdhury AT, Eisenmann ED, Cheng X, Pabla N, Mathijssen RHJ, Baker SD, Hu S, Sparreboom A, Talebi Z
Cancer Res Commun
June 14, 2024Pharmacokinetic assessment of low dose decitabine in combination therapies: Development and validation of a sensitive UHPLC-MS/MS method for murine plasma analysis.
Anabtawi N, Drabison T, Jin Y, Eisenmann ED, Sparreboom A, Govindarajan R, Baker SD, Ahmed E
J Chromatogr B Biomed Sci Appl
April 22, 2024Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, Baker SD, Patrick J, Ezzell JK, Rai J, Pan J, Rai SN, Stillwell C, Wunderlich M, Abdulrahim M, Goodwin TE, Hilinski G, Bennett CE, Hertlein E, Byrd JC
JCI Insight
January 11, 2024A new genomic framework to categorize pediatric acute myeloid leukemia.
Umeda M, Ma J, Westover T, Ni Y, Song G, Maciaszek JL, Rusch M, Rahbarinia D, Foy S, Huang BJ, Walsh MP, Kumar P, Liu Y, Yang W, Fan Y, Wu G, Baker SD, Ma X, Wang L, Alonzo TA, Rubnitz JE, Pounds S, Klco JM
Nat Genet
December 8, 2023Vincristine Disposition and Neurotoxicity are Unchanged in Humanized CYP3A5 Mice.
Li Y, Kazuki Y, Drabison T, Kobayashi K, Fujita KI, Xu Y, Jin Y, Ahmed E, Li J, Eisenmann ED, Baker SD, Cavaletti G, Sparreboom A, Hu S
Drug Metab Dispos
August 22, 2023Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study.
Bhatnagar B, Kohlschmidt J, Orwick SJ, Buelow DR, Fobare S, Oakes CC, Kolitz JE, Uy G, Stock W, Powell BL, Nicolet D, Hertlein EK, Mrózek K, Blachly JS, Eisfeld AK, Baker SD, Byrd JC
Blood Adv
June 1, 2023Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice.
Persaud AK, Bernier MC, Massey MA, Agrawal S, Kaur T, Nayak D, Xie Z, Weadick B, Raj R, Hill K, Abbott N, Joshi A, Anabtawi N, Bryant C, Somogyi A, Cruz-Monserrate Z, Amari F, Coppola V, Sparreboom A, Baker SD, Unadkat JD, Phelps MA, Govindarajan R
Nat Commun
April 7, 2023Determination and disposition of meta-iodobenzylguanidine in plasma and heart of transporter-deficient mice by UPLC-MS/MS.
Talebi Z, Jin Y, Baker SD, Addison D, Sparreboom A
J Chromatogr B Biomed Sci Appl
December 21, 2022TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion.
Eisenmann ED, Stromatt JC, Fobare S, Huang KM, Buelow DR, Orwick S, Jeon JY, Weber RH, Larsen B, Mims AS, Hertlein E, Byrd JC, Baker SD
Cancers (Basel)
October 12, 2022Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B.
Garrison DA, Jin Y, Talebi Z, Hu S, Sparreboom A, Baker SD, Eisenmann ED
Molecules
September 13, 2022A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.
Li Y, Jin Y, Taheri H, Schmidt KT, Gibson AA, Buck SAJ, Eisenmann ED, Mathijssen RHJ, Figg WD, Baker SD, Sparreboom A, Hu S
Pharmaceutics
August 27, 2022Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS/MS method.
Jin Y, Li Y, Eisenmann ED, Figg WD, Baker SD, Sparreboom A, Hu S
J Chromatogr B Biomed Sci Appl
July 7, 2022BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.
Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD, Blaser BW
Blood Adv
May 24, 2022Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA
Clin Cancer Res
March 28, 2022Preclinical and pilot study of type I FLT3 tyrosine kinase inhibitor, crenolanib, with sorafenib in acute myeloid leukemia and FLT3-internal tandem duplication.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD
Clin Cancer Res
March 23, 2022Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination.
Eisenmann ED, Garrison DA, Talebi Z, Jin Y, Silvaroli JA, Kim JG, Sparreboom A, Savona MR, Mims AS, Baker SD
Pharmaceutics
January 27, 2022The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children's Oncology Group and NRG Oncology study ARST1321.
Gartrell J, Panetta JC, Baker SD, Chen YL, Hawkins DS, Ostrenga A, Scharschmidt TJ, Spunt SL, Wang D, Weiss AR
Cancer Chemother Pharmacol
November 1, 2021Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.
Fornerod M, Ma J, Noort S, Liu Y, Walsh MP, Shi L, Nance S, Liu Y, Wang Y, Song G, Lamprecht T, Easton J, Mulder HL, Yergeau D, Myers J, Kamens JL, Obeng EA, Pigazzi M, Jarosova M, Kelaidi C, Polychronopoulou S, Lamba JK, Baker SD, Rubnitz JE, Reinhardt D, van den Heuvel-Eibrink MM, Locatelli F, Hasle H, Klco JM, Downing JR, Zhang J, Pounds S, Zwaan CM, Gruber TA
Blood Cancer Discov
October 6, 2021Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia.
Zavorka Thomas ME, Jeon JY, Talebi Z, Buelow DR, Silvaroli J, Campbell MJ, Sparreboom A, Pabla N, Baker SD
Blood Adv
September 14, 2021Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.
Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS
Kidney Int
September 13, 2021Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-positive AML.
Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, Uddin ME, Brinton LT, Nguyen J, Collins M, Lodi A, Sweeney SR, Campbell MJ, Sweet DH, Sparreboom A, Lapalombella R, Tiziani S, Baker SD
Molecular Cancer Therapeutics
July 30, 2021Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma.
Garrison DA, Jin Y, Uddin ME, Sparreboom A, Baker SD
J Chromatogr B Biomed Sci Appl
June 12, 2021Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.
Eisenmann ED, Talebi Z, Sparreboom A, Baker SD
Basic Clin Pharmacol Toxicol
February 2, 2021Targeting OCT3 attenuates doxorubicin-induced cardiac injury.
Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A
Proc Natl Acad Sci U S A
December 3, 2020TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD
JCI Insight
September 9, 2020DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD
Clin Transl Sci
September 9, 2020Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.
Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD
Pharmaceutics
August 20, 2020Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S
Pharmaceutics
May 20, 2020Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies.
Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD
J Chromatogr B Analyt Technol Biomed Life Sci
April 21, 2020A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury.
Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng MJHH, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS
Nat Commun
April 16, 2020Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK
Leukemia